EXO1 and pancreatic neoplasm: Furthermore, we tested the impact of EXO1 KO in the patient-derived FANCC-deficient pancreatic cancer cell line PL1140, which has a defect in FANCD2 monoubiquitylation that can be restored by complementation with wild-type FANCC (Supplementary Fig. 4j).